HIV Research for Prevention Conference, HIVR4P 2020

项目摘要 控制艾滋病毒的流行是可行的，但只有我们大力加强初级预防努力， 该方案旨在帮助处于危险中的青少年和成年人，并确保制定下一代预防方法。而 在扩大有效的生物医学预防和补充 行为和结构方法，一些群体和地区的新感染，包括在 美国不是在下降，而是在上升。根据多达五项新药物疗效试验的结果， 预防技术预计在2020/21年，预防领域将面临困难的决定，怀疑和 让执行受众不堪重负，并质疑社区。在这种背景下，艾滋病毒 2020年预防研究会议（HIVR 4P 2020）将是全球科学会议的关键， 在艾滋病毒预防的现状，重新调整优先事项，并制定未来十年的工作计划。的 会议将严格评估疫苗开发、单克隆抗体等方面的最新研究成果 干预措施，PrEP和其他基于ARV的方法，长效和长效制剂，其他新的 预防模式和相关的执行科学。11日在南非开普敦举行的 截至2020年10月15日，HIVR 4P 2020将有来自50多个国家的1，400名代表出席。 南非继续在产品开发和测试方面发挥重要作用， 美国的因此，在开普敦参加艾滋病毒4P方案将使代表们有机会受益于 了解在这一关键背景下的成功和挑战，同时参与广泛的科学和 来自美国、欧洲、亚洲和其他地区的专家与非洲同行进行政策交流。 HIVR 4P 2020的具体目标是： 1.召集全世界艾滋病毒预防和相关领域的专家，推动科学知识， 新的研究成果，并加强全球科学和社区合作; 2.推进基于证据和人权的艾滋病毒预防工作， 特别是处于风险和弱势群体，以减少健康差距，包括： 成年人、高负担环境中的妇女和女孩、流离失所人口、男男性行为者， 囚犯和其他被监禁的人，吸毒者，性工作者和变性人; 3.完善艾滋病毒预防研究议程，以反映已查明的机会和知识差距，包括： 下一代艾滋病毒疫苗和bNAb;更智能的分子输送系统，包括更长的 代理和多用途技术;进一步推广PrEP的挑战和机遇以及长期 PrEP的使用;在更广泛的性传播疾病和艾滋病毒的预防范围内， 生殖健康办法;在不断变化的类阿片使用模式下预防艾滋病毒;以及 跨疾病和风险领域的综合预防议程。 科学计划将按照沿着五个主题领域进行结构化：基础科学; PrEP和基于ARV的 预防;疫苗和bNAb临床试验;其他预防方式和交叉问题;以及 应用和实施科学。在全体会议上将强调贯穿各领域的问题， 将科学轨道与社区和领导观点联系起来。青年的参与 加强基础科学研究人员和相关领域研究人员的队伍建设， 相关科学和提供具体的财政支持。免费远程访问会议 介绍和海报以及强有力的社交媒体传播将确保覆盖范围超出那些能够 亲自出席并参加现场讨论。

Project Summary Epidemic control of HIV is feasible but only if we substantially strengthen our primary prevention efforts in adolescents and adults at risk and ensure the development of next-generation prevention methods. While much progress has been made in expanding effective biomedical prevention and in complementary behavioral and structural approaches, new infections in some groups and geographies, including in the United States, are not declining but are on the rise. With the results of up to five efficacy trials of new prevention technologies expected in 2020/21, the prevention field will face difficult decisions, skeptical and overburdened implementation audiences, and questioning communities. Against this background, the HIV Research for Prevention Conference 2020 (HIVR4P 2020) will be the key global scientific convening to reflect on the state of HIV prevention, recalibrate priorities, and map out a workplan for the coming decade. The conference will critically assess the latest research results in vaccine development, monoclonal antibody interventions, PrEP and other ARV-based approaches, long-acting and depot formulations, other novel prevention modalities, and relevant implementation science. Taking place in Cape Town, South Africa, on 11 to 15 October 2020, HIVR4P 2020 will have an attendance of 1,400 delegates from more than 50 countries. South Africa continues to play a significant role in product development and testing in cooperation with the United States. Attending HIVR4P in Cape Town will thus offer delegates the opportunity to benefit from learning about the successes and challenges in this critical setting while engaging in a broad scientific and policy exchange between specialists from the U.S, Europe, Asia and other regions with their African peers. The specific aims of HIVR4P 2020 are to: 1. Convene the world’s experts in HIV prevention and related fields to advance scientific knowledge, present new research findings, and enhance global scientific and community collaborations; 2. Advance evidence-informed and human rights-based HIV prevention that is tailored to the needs of particularly at risk and vulnerable groups to reduce health disparities including: adolescents and young adults, women and girls in high-burden settings, displaced populations, men who have sex with men, prisoners and other incarcerated people, people who use drugs, sex workers, and transgender people; 3. Refine HIV prevention research agendas to reflect identified opportunities and knowledge gaps, including: next generation of HIV vaccines and bNAbs; smarter delivery systems for molecules, including longer- acting and multi-purpose technologies; challenges and opportunities of further PrEP roll-out ad long-term PrEP use; integrated sexually transmitted infections (STI) and HIV prevention within broader sexual and reproductive health approaches; HIV prevention in the context of changing patterns of opioid use; and integrated prevention agendas that cut across disease and risk areas. The scientific program will be structured along five thematic areas: Basic science; PrEP and ARV-based prevention; Vaccines and bNAbs clinical trials; Other prevention modalities and cross-cutting issues; and Applied and implementation science. Cross-cutting aspects will be highlighted in plenary talks that also connect the scientific tracks with community and leadership perspectives. The participation of young researchers, basic scientists and researchers in related fields will be strengthened by active solicitation of relevant science and the provision of specific financial support. Free remote access to conference presentations and posters and robust social media dissemination will ensure reach beyond those able to attend in person and join the discussions on site.